ArticleHaematologica2017
Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition.
Article in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.Nature communications · 2021Pooled it
- Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin.PloS one · 2018Trial
- Review
- Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia.Cancers · 2024Review
- NPM 1 Mutations in AML-The Landscape in 2023.Cancers · 2023Review
- Review
- Targeted therapy in NPM1-mutated AML: Knowns and unknowns.Frontiers in oncology · 2022Review
- Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.International journal of molecular sciences · 2021Review
- T cell optimization for graft-versus-leukemia responses.JCI insight · 2020Review
- Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition.Cancer immunology, immunotherapy : CII · 2020Article
- B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint Receptor Expression, and European Leukemia Net Risk Profiles.Frontiers in oncology · 2020Article
- High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with ConcomitantInternational journal of molecular sciences · 2019Article
- Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia.Oncotarget · 2019Article
- Cancer immune therapy for myeloid malignancies: present and future.Seminars in immunopathology · 2019Review
- Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia.JCO precision oncology · 2019Article
- Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin.PloS one · 2019Article
- Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.JCI insight · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.